SYNERGISTIC INTERACTION OF EPINEPHRINE AND CALCIUM IONOPHORE IN PLATELET AGGREGATION
Idrees Farooq Butt, Sheikh Arshad Saeed*, Saima N Waqar*, Muhammad Aslam
Background: Platelets play a key role in haemostasis.
Human Platelets contain a2 adrenergic receptors, which are coupled with guanine
nucleotide proteins (G proteins). The platelet activation involves a number of
receptors for agonists. It has also been shown that most of the agonists act in
synergy and potentiate the effects of each other. The present experimental
study was designed to study the potentiation of epinephrine on human platelets
by calcium ionophore A23187 and the possible role of calcium in platelet
aggregation as a second messenger.
Methods: Study was carried out at Department of Biological Sciences Aga
Key Words: Platelet aggregation, Epinephrine, calcium ionophore A23187, yohimbine, diltiazem, verapamil and SNAP.
Platelets are known to be engaged in a variety of biochemical and molecular activities designed to prevent haemorrhage and maintain vascular integrity. To accomplish these tasks, platelets have surface receptors that can bind adhesive glycoproteins (GP) of various types and thus promote platelet adhesiveness, aggregation and release reaction. The platelet activation process involves a number of receptors for agnosits such as adenosine diphosphate (ADP), epinephrine, thrombin, collagen, fibrinogen, thromboxame A2, (TXA2) and platelet activating factor (PAF). It also involves several signal transduction pathways, including phosphoinositide metabolism, arachidonic acid release and conversion into thromboxame A2, calcium mobilization and phosphorylation of a number of different target proteins. Many platelet agonists, like thrombin, ADP, PAF, epinephrine and 5 hydroxytryptamin (5 HT) initiate platelet activation by binding to transmembrane receptors on platelets coupled with guanosine triphosphate (GTP) binding proteins (G proteins). The G proteins mediate a variety of cellular processes by activating different effector molecules, like adenylyl cyclase, phospholipase C (PLC) or ion channels1. Epinephrine a very important hormone of the adrenal gland, can influence platelet aggregation like other agonists. Epinephrine receptors have been classified as alpha and beta with respective subtypes α 1. α 2, β1 and β 2. Human platelets contain both α 1, and α 2, adrenoceptors. The α 2 adrenoceptor is identified as being primarily responsible for mediating the response to natural agonists2,3. The receptor (α2) is a G.inhibitory (Gi) protein linked receptor that contains seven membrane spanning hydrophobic domains, an extracellular binding site and a series of cytoplasmic binding loops that are the sites of interaction with Gi proteins in the cytoplasm4. It is also known that activation of α2 adrenergic receptors in human platelets inhibit the adenyl cyclase system through coupling to a Gi protein5. It is considered that inhibition of adenyl cyclase system is not sufficient to cause platelet aggregation, but may be sufficient to amplify the activation induced by other agonists6. Indeed, the signal processing mechanisms which mediate the platelet stimulating effect of epinephrine have not so far been clarified despite extensive research 7-11.
Calcium ionophore A23187 is thought to activate cellular phospholipases and thus causes calcium entry into the cell from the extracellular fluid (ECF). It has also been shown that most of the agonists act in synergy and potentiate the effect of each other12. The phenomenon of agonist synergism is very important physiologically and has been demonstrated in many pairs of agonists13-18. The possible mechanism of this synergistic action is by raising cytoplalsmic concentration of Ca++.The first agonist or initial stimulus “primes” the platelets for an augmented response to a second agonist19. The cytoplasmic Ca++ concentration can be increased by two ways, either by causing an influx of Ca++ into the cell from ECF or by causing a release of Ca++ from intracellular stores. The role of other effectors and second messengers is not well understood. The present study was designed to study the potentiation of epinephrine by A23187 on human platelets and to find out the molecular basis of this potentiation.
MATERIAL AND METHODS
This experimental study was conducted on 200 samples
of platelets at Department of Biological Sciences Aga Khan University,
Platelet aggregation was measured with platelet aggregometer (Model 440, Chronolog Corporation-USA) using the technique described originally by Born . The changes in optical density were recorded on omniscribe chart recorder. Temperature (37Ċ), stirrer speed (1100 r.p.m) and speed of chart recorder (25 mm per minute) were kept constant. The cuvette containing 500 μl PPP was placed in PPP reference well. The cuvettes containing PRP were placed in the incubation wells. At the time of testing each cuvette contained 450 μl PRP and a Teflon coated stirrer bar. The final volume of PRP under test was made 500 μl by adding 50 μl of the test drug. The resulting aggregation response was recorded for 5 minutes after challenge by the agonists. Aggregation was induced with epinephrine and A23187 and subthreshold concentration determined for each agonist. To determine the synergistic effect of epinephrine and A23187, we added subthreshold concentration of each agonist together. Successive samples of PRP were tested with different concentrations of drug. Once, the antiplatelet activity of various inhibitors (Yohimbine, Diltiazem, Verapamil, SNAP) against agonists was determined, the dose response curves were constructed to calculate IC 50 (Half maximal inhibitory concentration)values.
The Platelet aggregation induced by different concentrations of epinephrine (0.1, 0.2, 0.5, 1.0, 5.0 μM) was recorded. The results indicated 0.2uM as the subthreshold concentration that does not induce optimal platelet aggregation. The platelet aggregation induced by different concentrations of A23187 (0.25, 0.50, 1.0, 2.0, 5.0 μM) was also recorded. The results indicated, 0.5 uM as the subthreshold concentration for A23187. To establish the synergistic effect of epinephrine and A23187, the PRP was challenged with subthreshold concentration of epinephrine (0.2 μM) and subthreshold concentration of A23187 (0.5 μM) simultaneously and an optimal platelet aggregation response (35% intensity of aggregation) was observed. The results shown in Fig-1 manifest that optimal platelet aggregation is only recorded when platelets are challenged with the subthreshold concentrations of epinephrine and A23187 together. While decreasing the concentration of any one of the agonist and keeping constant the concentration of the other agonist, does not produce optimal platelet aggregation, thus establishing the synergistic effect of epinephrine and A23187.
Fig-1a: Percentage platelet aggregation responses induced by synergistic effect of subthreshold concentration (0.5mM) of A-23187 and different subthreshold concentrations (0.005, 0.01, 0.05, 0.1, 0.2mM) of Epinephrine
Fig-1b: Percentage platelet aggregation responses induced by synergistic effect of subthreshold concentrations (0.2mM) of epinephrine and different subthreshold concentrations (0.6, 0.12, 0.25, 0.5 mM) of calcium ionophore A-23187.
When PRP was pretreated with different concentrations, (0.01, 0.05, 0.1 μM) of Yohimbine an α2 adrenergic receptor blocker and then the platelet aggregation was induced by adding simultaneously the subthreshold concentration of epinephrine (0.2 μM) and A23187 (0.5 μM), there was inhibition of platelet aggregation in a dose dependent manner (Fig-2), IC50 value for the Yohimbine was calculated to be 0.05 μM. Similarly when the PRP was pretreated with different concentrations (10,20,40,60 μM) of calcium channel blocker, Verapamil and different concentrations (10,20,40,60,80,100 μM) of Diltiazem, another calcium channel blocker, it inhibited the platelet aggregation induced by subthreshold concentration of epinephirine (0.2 μM) and subthreshold concentration (0.5 μM) of A23187 in dose dependent manner . A dose response curve shown in Fig-3 manifests a dose dependent inhibitory effect of both the Verapamil and Diltiazem. The IC50 values of Verapamil and Diltiazem as calculated from the curve are 22 μM and 50 μM respectively. When PRP was pretreated with different concentrations (0.1,0.2,0.4 μM) of SNAP, a nitric oxide (NO) donor and then the platelet aggregation was induced by adding together the subthreshold concentrations of epinephrine (0.2 μM) and A23187 (0.5 μM, the platelet aggregation was inhibited in a dose dependent manner Fig-4. Dose response curve was constructed and IC50 value was calculated to be 0.5μM.
Fig -2 Effect of different concentrations (0.1, 0.05, 0.01mM) of Yohimbine (an a2 adrenergic receptor blocker) on platelet aggregation induced by subthreshold concentrations of Epinephrine (0.2mM) and A-23187 (0.5mM) shown as control
The results of the present study have shown that there is potentiation of epinephrine effects by A23187 in human platelets. Our results also indicate that the platelet activation induced by epinephrine is mediated through α2 adrenergic receptors and ther is a definite role of Ca ++ in this synergism. Furthermore the results also exhibit that calcium channel blocking agents inhibit the platelet aggregation induced as a result of epinephrine, A23187 synergism. While this synergism was also inhibited by SNAP (a nitric oxide donor).
Fig-3: Dose response inhibitory effect of verapamil and diltiazem on platelet aggregation induced by subthreshold concentration of epinephrine (0.2mM) and A23187 (0.5mM). Data is Mean ±SEM (n=5)
Fig-4: Effect of different concentrations (0.4, 0.2, 0.1mM) of SNAP (nitric Oxide donor) on platelet aggregation induced by subthreshold concentrations of epinephrine (0.2mM) and A23187 (0.5 mM) shown as control
Fig -5: Proposed platelet model depicting the role of Gi protein and calcium channels during coactivation by epinephrine and A-23187. Gibg subunit activates PLC, forming Inositol triphosphate (IP3) and diacylglycerol (DAG).IP3 causing release of Ca++ from dense tubular system (DTS) while A23187 promoting Ca++ entry into the cytoplasm from outside. NO from exogenously added SNAP (NO donor) inhibits platelet aggregation through production of cGMP. The cGMP activates protein kinase G (PKG) which inhibits PLC induced IP3 formation.
In our proposed platelet model, (Fig-5) epinephrine and A23187 synergism raises cytosllic Ca++ concentration on one hand by release from intracellular stores (dense tubular system) and on the other hand by increased influx from the extracellular fluid. Similar mechanism of agonist syndergism is known among other agonists also and is considered to occur due to activation of calcium signaling cascade. Recent studies have shown that βχ subunits of activated Gi protein can also activate phospholipase C (PLC)21-22. Activation of PLC pathway leads to an increase in cytosolic Ca++ due to its release from internal stores i.e dense tubular system (DTS) by inositol triphosphate (IP3) or through store depletd calcium influx23-24. The platelet cell membrane has limited permeability to calcium but is penetrated by several channels capable of permitting calcium influx. The calcium channels are protein macromolecules. Different types of calcium channels have been identified. Based on the stimulus required for opening of channels, there are voltage dependent calcium channels (VDCC), receptor operated channels (activated by binding of a chemical ligand to receptor) and second messenger operated channels (cAMP dependent channels). Most of the calcium influx during platelet activation results from passage through receptor operated calcium channels12. But the reagents that block VDCC, like Verapmil and Diltiazem, can also prevent elevation of intracellular calcium induced by several agonists 12-14.
To study the molecular basis of this potentiation, SNAP, was used that inhibited the platelet aggregation induced by the synergistic interaction of subthresthold concentrations of epinephrine and A23187. These results suggest that this synergism is sensitive to NO generation. Platelets contain an abundance of cAMP and cGMP dependent protein kinases which are activated by NO and inhibit PLC induced IP3 and thramboxane receptors thus inhibiting platelet aggregation24,25. The intracellular signaling involved in this synergism is likely to be mediated through stimulation of PLC of βχ subunits of Gi protein which in turn stimulates IP3 production and thus mobilinze Ca ++ from intracellular stores in DTS. The DTS is rich in IP3 receptors and Ca ++ is released whenever IP3 binds to its receptor. Our results are in conformity with the results of another study where the role of NO in inhibiting the platelet aggregation has been claimed25. In another recent study  it has been suggested that Gi and Gq proteins activation lead to PLC stimulation and Ca ++ signaling when the synergistic interaction of epinephrine and 5-hydroxytryptamine was studied. They also observed the inhibitory effect of SNAP on this synergism. The results are similar to this study. The results of this study are in agreement with another similar study18 where potentation of A23187 and epinephrine has been shown. These workers have also shown the inhibitory effect of calcium channel blocker, Diltiazem. But these workers did not explain intracellular signaling involved in this potentiation. In conclusion, our results reveal that potentiation of epinephrine by A23187 involves raised cytosolic Ca++ concentration as a result of increased Ca ++ influx from ECF and simultaneous mobilization of Ca++ from intracellular stores by stimulation of PLC by βχ submit of Gi protein.
The study also points to the communication between two different types of receptors that exhibit synergism i.e. Gi protein linked α2 receptor and calcium channels. In recent days, there is growing evidence for such cross talk between different receptors that leads to platelet aggregations 26-27
This study was supported by
1. Siess W. Molecular mechanism of platelet activation. Physiol Rev 1989;69:58-178.
2. Grant JA, Scrutton MC. Novel α2 adrenoceptors primarily responsible for inducing human platelet aggregation. Nature 1979;277:659-61.
3. Homcy CJ. Garham RM. Molecular characterization of adrenergic receptors. Circ Res 1985:635-650.
4. Aktories K, Jakobs H. Eipnephrine inhibits adenylate cyclase and stimulates a GTPase in human platelet membrances via alpha-adrenoceptors. FEBS lett 1981;130: 235-38.
5. Connolly TM, Limibird LE. The influence of Na+ on the alpha adrenergic receptor system of human platelets. A method for removal of extraplatelet Na+: Effects of Na+ removal on aggregation secretion and cAMP accumulation. J Biol Chem 1983;258:3907-12.
6. Steen VM, Tysnes OB, Holmsen H. Synergism between thrombin and adrenaline (epinephrine) in human platelets Marked potentitation of inositol phospholipids metabolism. Biochem J 1988;253:581-6.
Banga HS, Somins ER, Brass LF, Rittenhouse SE. Activation of
phospholipase A and C in human platelets exposed to epinephrine: role of
glycoprotein II b/III a and dual role of epinephrine. Proc Natl Acad Aci
9. Steen VM, Holmsen H, Aarbakke G. The platelet stimulating effect of adrenaline through agonist. Thromb Haemost 1993;70(3):506-13.
10. Razi MS, Butt IF, Ayub M, Aslam M, Hameed W, Badar A, et al. Synergistic Interaction of Adenosine diphosphate-Epinephrine and Epinephrine- Collagen in aggregation of Human Platelets. J Ayub Med Coll Abbottabad 2004;16(3):20-24.
11. Ware JA, Smith M, Salzman EW. Synergism of platelet aggregating agents: Role of elevation of cytoplasmic calcium. J Clin Invest 1987; 80:267-71.
12. Shah BH, Siddiqui A, Qureshi KA, Khan M, Rafi S, Ujan VA et al. Coactivation of Gi and Gq proteins exerts synergistic effect on human platelet aggregation through activation of phosphlipase c and Ca ++ signaling pathways. Exp Mol Med 1999;31:42-46.
13. Grant J A, Scrutton MC. Positive interaction between agonists in the aggregation response of human blood platelets: Interaction between ADP, adrenaline and vasopressin. Br J Haematol 1980;44:109-125.
14. Steen VM, Holmsen H. Synergism between thrombin and epinephrine in human platelets: Different dose-response relationship for aggregation and dense granule secretion. Thromb Haemost 1985; 30:680-9.
15. Packham MA, Guccione MA, Chang PL, Mustard JF. Platelet aggregation and release; effects of low concentrations of thrombin or collagen. Am J Physiol 1973; 225:38-47.
16. Figures WR, Scearce LM, Wachtfogel Y, Chen J, Colman RF, Colman RW. Platelet ADP receptor and α2 adrenorceptor interaction. J Biol Chen 1986; 261:5981-5986.
17. Sation M, Salzman EW, Smith H, Ware JA. Activation of ptorein kinase C in platelets by epinephrine and A23187; Correlation with fibrinogen. Blood 1989;74:2001-7.
18. Kinlough-Rathbone RL, Mustard JF. Synergism of agonists. In Platelet Response and Metabolism. Holmser H; editor CRB Press, Boca Ration E.L 1986;193-207.
19. Born GVR. Adenosine diphosphate as a mediator of platelet aggregation in vivo; an editorial view. Circulation 1985;72(4):741-6.
21. Banno Y, Asano T, Nozawa Y. Stimulation by G Protein βγ sub units of phopholipase C isoforms in human platelets. Thromb Haemost 1998;79:1008-1013.
22. Berridge MJ. Inositol trisphosphate and calcium signaling Nature 1993;361: 315-325.
23. Hemskerk JWM, Sage O. Calcium signaling in platelets and other cells. Platelets 1994;5:295-316.
24. Wang GR, Zhu Y, Haluskha PV,
Lincoln TM, Mendelsohn ME. Mechanism of
platelet inhibiton by nitric oxide: in vivo phosphorylation of thromboxane
receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci
25. Wang X, Yanagi S, Yang C, Inatome R, Yamunura H. Tyrosine phosphorylation and SYK activation are involved in thrombin induced aggregation of epinephrine-potentiated platelets. JBiochemist 1997;121:322-330.
26. Nieswandt B, Bergmeier W, Eckly A, Schutle V, Ohlmann P, Cazenave JP, Ziringibl H et al. Evidence for cross cross talk between gloycoprotein VI and Gi coupled receptors during collagen induced platelet aggregation. Blood 2001;97 (12); 3829-3825.
27. Butt I F, Saeed S A, Rasheed H, Aslam M. Role of Phosphatidyl Inositol 3 Kinase in Epinephrine and Calcium Iononophore A 23187 induced Platelet Aggregation. Pak Armed Forces Med J 2004; 54 (1): 86-91.
Address For Correspondence: